Trifluridine/tipiracil plus bevacizumab improves OS in mCRC

Share :
Published: 7 Feb 2023
Views: 225
Dr Josep Tabernero - Vall d’Hebron University Hospital, Barcelona, Spain

Dr Josep Tabernero speaks to ecancer about the SUNLIGHT study.

This study investigated trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer.

The study found that trifluridine/tipiracilTPI plus bevacizumab provides a statistically significant and clinically meaningful 3.3-month improvement in overall survival, extending mOS up to 10.8 months, with a 39% reduction in the HR of death in patients with refractory mCRC and with a predictable and acceptable safety profile.

He concludes by discussing the clinical impact of these results.